artificial decapeptide antagonist to gonadotropin releasing hormone (GnRH). it is advertised by Praecis pharmaceuticals as Plenaxis. Praecis introduced in June 2006 that it become voluntarily taking flight the drug from the market.
Used in the palliative treatment of advanced prostate cancer. Abarelix is a luteinizing hormone agonist that results in suppression of testicular or follicular steroidogenesis.
For palliative treatment of advanced prostate cancer.
Abarelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion.